- Record: found
- Abstract: found
- Article: not found
Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?
Hong Fang
1 ,
Prashant Kapoor
2 ,
Wilson I Gonsalves
2 ,
Lori A Frederick
1 ,
David Viswanatha
1 ,
Matthew T Howard
1 ,
Rong He
1 ,
William G Morice
1 ,
Ellen D McPhail
1 ,
Patricia T Greipp
3 ,
Stephen M Ansell
2 ,
Robert A Kyle
2 ,
Morie A Gertz
2 ,
Jonas Paludo
2 ,
Jithma Abeykoon
2 ,
Rebecca L King
1
Jul 03 2018
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Lymphoplasmacytic lymphoma (LPL) remains a poorly defined entity, even with the discovery of MYD88L265P mutations and association with Waldenström macroglobulinemia (WM). Among bone marrow (BM)-based, low-grade B-cell lymphoma with plasmacytic differentiation (LGBLPD) and immunoglobulin M (IgM) paraproteins, we sought to determine whether MYD88L265P defines a distinct entity and can help refine diagnostic criteria for LPL.